US FDA approves Breckenridge Pharma's...
Home  »  Community News  »  US FDA approves Brec...
US FDA approves Breckenridge Pharma’s gabapentin oral solution
Pharma News

Boca Raton, Florida
Saturday, March 19, 2016, 15:00 Hrs  [IST]

The US Food and Drug Administration (FDA) has granted final approval to Breckenridge Pharmaceutical’s  Abbreviated New Drug Application for Gabapentin oral solution 250 mg per 5 ml, which is AA rated to Neurontin, a drug marketed by Pfizer. The product developer, Tris Pharma, will manufacture and supply, and Breckenridge will market and distribute the product.

The Gabapentin oral solution annual generic sales totaled $9.3 million based on IMS Health sales data. Gabapentin is indicated as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.

The product launch plans are being finalised and the first shipment will occur shortly.

Breckenridge Pharmaceutical, Inc. is a privately-held own label distributor that performs pharmaceutical research and development as well as marketing and distribution in the US.

Courtesy – Pharmabiz

Leave a reply

You must be logged in to post a comment.